<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00148876</url>
  </required_header>
  <id_info>
    <org_study_id>GBG 26</org_study_id>
    <secondary_id>BIG3-05</secondary_id>
    <nct_id>NCT00148876</nct_id>
  </id_info>
  <brief_title>TBP Study With Capecitabine Plus Minus Trastuzumab</brief_title>
  <official_title>A Multicenter Randomized Phase III Study to Compare Capecitabine Alone or in Combination With Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer and Progression After Previous Treatment With Trastuzumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Breast Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>German Breast Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is done in patients having Breast Cancer with metastasis (patients with positive&#xD;
      receptor HER2) whose disease progressed after receiving Trastuzumab.&#xD;
&#xD;
      The primary objective of this study is to compare the time until disease progression between&#xD;
      the Treatment Arm CAPECITABINE and the Treatment Arm CAPECITABINE + TRASTUZUMAB&#xD;
&#xD;
      The study has also other secondary and tertiary objectives.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial design:&#xD;
&#xD;
      Prospective, multi-center, controlled, non blinded, randomized phase III Study&#xD;
&#xD;
      Treatment:&#xD;
&#xD;
      Patients with HER2 positive metastatic breast cancer and progression after previous treatment&#xD;
      with trastuzumab are being randomized to either:&#xD;
&#xD;
      A. Capecitabine 2500 mg/m² orally day 1-14 q day 22 until progression * and discontinuation&#xD;
      of Trastuzumab&#xD;
&#xD;
      B. Capecitabine and Trastuzumab:&#xD;
&#xD;
      Capecitabine 2500 mg/m² orally day 1-14 q day 22 until progression * Trastuzumab 6 mg/kg body&#xD;
      weight every 3 weeks i.v. as a 90 min infusion until progression *&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      To compare the time to disease progression in patients with HER2 positive metastatic breast&#xD;
      cancer and progression after previous treatment with trastuzumab randomized to capecitabine&#xD;
      alone or in combination with trastuzumab.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      To compare the objective response rate between the two arms To compare the duration of&#xD;
      response To compare the clinical benefit defined as CR, PR, or stable disease &gt; 24 weeks&#xD;
      between the two arms To evaluate the safety of the capecitabine + trastuzumab combination To&#xD;
      compare overall survival between the two arms&#xD;
&#xD;
      Tertiary objective:&#xD;
&#xD;
      To determine the HER2 status in tissue collected directly before study entry&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any progression of disease or disease related death of a patient</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any response documented according to the RECIST Criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from CR or PR until progression of disease or death due to any cause</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any response and stable disease of &gt;24 weeks duration documented according to the RECIST Criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any grade III/IV toxicity (NCI-CTC version2.0).Premature treatment discontinuation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any death of a patient</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">482</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine 2500 mg/m² orally day 1-14 q day 22 until progression and discontinuation of Trastuzumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine and Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine 2500 mg/m² orally day 1-14 q day 22 until progression + Trastuzumab 6 mg/kg body weight every 3 weeks i.v. as a 90 min infusion until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 2500 mg/m² orally day 1-14 q day 22</description>
    <arm_group_label>Capecitabine</arm_group_label>
    <arm_group_label>Capecitabine and Trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab 6 mg/kg body weight every 3 weeks i.v.</description>
    <arm_group_label>Capecitabine and Trastuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent prior to beginning specific protocol procedures, including&#xD;
             expected cooperation of the patients for the treatment and follow-up, must be obtained&#xD;
             and documented according to the local regulatory requirements.&#xD;
&#xD;
          2. Pathologically confirmed carcinoma of the breast.&#xD;
&#xD;
          3. Locally advanced or metastatic stage of disease not suitable for surgery or&#xD;
             radiotherapy alone.&#xD;
&#xD;
          4. HER2-overexpression of the primary or metastatic tumor tissue detected by&#xD;
             immunohistochemistry (DAKO) 3+ or gene namplification detected by FISH. HER2-positive&#xD;
             primary tumours with HER2-negative metastasis can be included.&#xD;
&#xD;
          5. Disease progression during or after previous chemotherapy and trastuzumab treatment as&#xD;
             follows (Trastuzumab has to be given previously for at least 12 weeks, treatment free&#xD;
             interval of trastuzumab for a maximum of 6 weeks):&#xD;
&#xD;
               -  Taxanes + trastuzumab given as adjuvant therapy&#xD;
&#xD;
               -  Taxanes + trastuzumab given as first line therapy for palliation&#xD;
&#xD;
               -  Trastuzumab given as first line therapy for palliation alone or in combination&#xD;
                  with chemotherapeutic agents other than capecitabine or taxanes&#xD;
&#xD;
          6. No more than 1 chemotherapy for palliation (max. Adriamycin dose &lt; or = 400 mg/m²;&#xD;
             Epirubicin &lt; or = 600 mg/m²)&#xD;
&#xD;
          7. Patients must have either measurable or nonmeasurable target lesions according to the&#xD;
             RECIST criteria (see Appendix 6)&#xD;
&#xD;
          8. At least 4 weeks since radiotherapy, with full recovery. The measurable disease must&#xD;
             be completely outside the radiation portal or there must be pathologic proof of&#xD;
             progressive disease&#xD;
&#xD;
          9. At least 4 weeks since major surgery with full recovery.&#xD;
&#xD;
         10. Complete radiology and tumor measurement work up within 4 weeks prior to registration:&#xD;
&#xD;
         11. Karnofsky performance status evaluation &gt; or = 60%&#xD;
&#xD;
         12. Age &gt;18 years.&#xD;
&#xD;
         13. Absolute neutrophil count &gt; or =1,500 cells/microL, platelet count &gt; or =100,000&#xD;
             cells/microL.&#xD;
&#xD;
         14. Bilirubin &lt; or = 2x the upper limit of normal for the institution (ULN); elevation of&#xD;
             transaminases and alkaline phosphatase &lt; 2.5x ULN or &lt;5x ULN for patients with liver&#xD;
             metastases.&#xD;
&#xD;
         15. Creatinine &lt; or = 2.0 mg/dl.&#xD;
&#xD;
         16. Left ventricular ejection fraction (LVEF) by cardiac ultrasound of &gt; or = 50%.&#xD;
&#xD;
         17. If of childbearing potential, pregnancy test is negative. In addition the patient&#xD;
             agrees to use an effective method to avoid pregnancy for the duration of the study.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Known hypersensitivity reaction to the compounds or incorporated substances or known&#xD;
             dihydropyrimidine dehydrogenase deficiency.&#xD;
&#xD;
          2. Concurrent immunotherapy or hormonal therapy (antihormonal, contraceptive and/or&#xD;
             replacement therapy). Bisphosphonates may be continued.&#xD;
&#xD;
          3. Parenchymal brain metastases, unless adequately controlled by surgery and/or&#xD;
             radiotherapy with complete resolution of symptoms and of all steroids.&#xD;
&#xD;
          4. Life expectancy of less than 3 months.&#xD;
&#xD;
          5. Serious intercurrent medical or psychiatric illness that may interfere with the&#xD;
             planned treatment (including severe pulmonary conditions, AIDS and serious active&#xD;
             infection).&#xD;
&#xD;
          6. History of congestive heart failure or other significant uncontrolled cardiac disease.&#xD;
&#xD;
          7. History of other malignancy within the last 5 years which could affect the diagnosis&#xD;
             or assessment of breast cancer.&#xD;
&#xD;
          8. Concurrent treatment with other experimental drugs. Participation in another clinical&#xD;
             trial with any investigational not marketed drug within 30 days prior to study entry.&#xD;
&#xD;
          9. Treatment with sorivudine or derivates e.g. brivudin&#xD;
&#xD;
         10. Pregnant or nursing women.&#xD;
&#xD;
         11. Male patients.&#xD;
&#xD;
         12. The patient must be accessible for treatment and follow-up. Patients registered on&#xD;
             this trial must be treated and followed at the participating centre which could be the&#xD;
             Principal or Co- investigator's site.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunter von Minckwitz, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Breast Group Forschungs GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johann Wolfgang Goethe Universität, Universitätsfrauenklinik</name>
      <address>
        <city>Frankfurt / Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.germanbreastgroup.de</url>
    <description>Click here for more information about this study: TBP Study</description>
  </link>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>February 22, 2011</last_update_submitted>
  <last_update_submitted_qc>February 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2011</last_update_posted>
  <keyword>Progression after treatment with Trastuzumab</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>Palliative Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

